RASP (Actavia Life Sciences) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2024)


What is Actavia Life Sciences ROE % Adjusted to Book Value?

Actavia Life Sciences RASP -87.50% ROE % Adjusted to Book Value is 0.00% as of Mar. 2024.

Actavia Life Sciences's ROE % for the quarter that ended in Mar. 2024 was 0.00%. Actavia Life Sciences's PB Ratio for the quarter that ended in Mar. 2024 was N/A. Actavia Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was N/A.

Actavia Life Sciences ROE % Adjusted to Book Value Related Terms

Actavia Life Sciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences ROE % Adjusted to Book Value Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.19 0.00 0.00 0.00 0.00

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RASP vs BWV, FNCH, CWBR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Actavia Life Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's ROE % Adjusted to Book Value falls into.


Actavia Life Sciences ROE % Adjusted to Book Value Calculation

Actavia Life Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Actavia Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Actavia Life Sciences (RASP) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2024. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Actavia Life Sciences and its competitors.
Is Actavia Life Sciences' ROE % Adjusted to Book Value too high?
Actavia Life Sciences' current ROE % Adjusted to Book Value is 0.00%.
How does Actavia Life Sciences' ROE % Adjusted to Book Value compare to BWV and FNCH?
Actavia Life Sciences' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Actavia Life Sciences and its competitors. Actavia Life Sciences's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actavia Life Sciences stock overvalued right now?
Actavia Life Sciences (RASP) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.